Collegium Pharmaceutical Inc buy tamam
Start price
21.06.18
/
50%
€24.70
Target price
03.06.19
€36.08
Performance (%)
-57.85%
End price
03.06.19
€10.41
Summary
This prediction ended on 03.06.19 with a price of €10.41. Massive losses of -57.85% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Collegium Pharmaceutical Inc | 2.051% | 2.051% | 33.557% | 60.484% |
| iShares Core DAX® | -1.764% | 2.259% | 15.213% | 61.619% |
| iShares Nasdaq 100 | -1.632% | -0.193% | 3.293% | 100.420% |
| iShares Nikkei 225® | -2.451% | 4.086% | 17.198% | 50.705% |
| iShares S&P 500 | -2.252% | -0.151% | 0.574% | 63.730% |
Comments by tamam for this prediction
In the thread Collegium Pharmaceutical Inc diskutieren
Collegium in a huge potential market and solid operational momentum
Collegium continues to see a nice ramp-up in sales of Xtampza.
First-quarter revenues should be very strong as well, as regulatory action following the opioid crisis could make Xtampza a big winner.
(Vom Mitglied beendet)